DexCom, Inc. (NASDAQ:DXCM) – Investment analysts at William Blair boosted their Q3 2019 earnings estimates for shares of DexCom in a research report issued to clients and investors on Wednesday, July 31st. William Blair analyst M. Kaczor now expects that the medical device company will post earnings of $0.16 per share for the quarter, up from their prior estimate of $0.11. William Blair also issued estimates for DexCom’s Q4 2019 earnings at $0.71 EPS, FY2019 earnings at $0.91 EPS, Q1 2020 earnings at ($0.13) EPS, Q2 2020 earnings at $0.03 EPS, Q3 2020 earnings at $0.26 EPS, Q4 2020 earnings at $0.93 EPS and FY2020 earnings at $1.11 EPS.
Several other equities research analysts have also recently commented on DXCM. BTIG Research reaffirmed a “hold” rating on shares of DexCom in a research note on Thursday, August 1st. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research note on Tuesday, July 23rd. Northland Securities reaffirmed a “hold” rating and set a $125.00 target price on shares of DexCom in a research note on Thursday, June 6th. TheStreet raised DexCom from a “d+” rating to a “c” rating in a research note on Friday, June 28th. Finally, UBS Group raised their target price on DexCom from $140.00 to $160.00 and gave the stock a “neutral” rating in a research note on Thursday, August 1st. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. DexCom presently has a consensus rating of “Buy” and a consensus target price of $165.88.
NASDAQ DXCM opened at $147.65 on Monday. The business’s 50 day simple moving average is $149.62. DexCom has a one year low of $105.05 and a one year high of $161.30. The firm has a market capitalization of $13.46 billion, a PE ratio of 492.17 and a beta of 0.80. The company has a quick ratio of 5.64, a current ratio of 6.05 and a debt-to-equity ratio of 1.56.
DexCom (NASDAQ:DXCM) last released its earnings results on Wednesday, July 31st. The medical device company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.01 by $0.07. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The business had revenue of $336.40 million during the quarter, compared to analysts’ expectations of $304.40 million. During the same quarter last year, the firm posted ($0.10) earnings per share. The firm’s revenue was up 38.7% on a year-over-year basis.
Large investors have recently made changes to their positions in the business. Gradient Investments LLC bought a new position in shares of DexCom in the second quarter valued at approximately $25,000. Steward Partners Investment Advisory LLC bought a new position in shares of DexCom in the second quarter valued at approximately $31,000. Wealthcare Advisory Partners LLC bought a new position in shares of DexCom in the second quarter valued at approximately $37,000. Private Ocean LLC bought a new position in shares of DexCom in the first quarter valued at approximately $36,000. Finally, Bremer Bank National Association bought a new position in shares of DexCom in the first quarter valued at approximately $42,000. Institutional investors and hedge funds own 96.21% of the company’s stock.
In other DexCom news, CEO Kevin R. Sayer sold 6,000 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $115.73, for a total value of $694,380.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Patrick Michael Murphy sold 400 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $116.92, for a total value of $46,768.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 63,065 shares of company stock worth $8,207,313. Corporate insiders own 0.88% of the company’s stock.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Story: What are the disadvantages of after-hours trading?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.